Wire Stories

Entry Period: Mar 10 � Jun 10, 2023 (JST) TOKYO--(BUSINESS WIRE)--The ASEAN-Japan Centre (AJC) has launched the "Golden Bridge Short…

3 years ago

Netcracker Highlights Ongoing Commitment to Region at DTW Asia 2023

Netcracker to Discuss Telco to Techco Transformation and New Approaches to Maximize Growth and Revenue at Bangkok Event WALTHAM, Mass.--(BUSINESS…

3 years ago

Zuora Expands India Footprint with New Office in Chennai

With a 200-person capacity, engineering talent at the new office will help drive global product innovation in the Subscription Economy…

3 years ago

Zuora Expands India Footprint with New Office in Chennai

With a 200-person capacity, engineering talent at the new office will help drive global product innovation in the Subscription Economy…

3 years ago

Zuora Expands India Footprint with New Office in Chennai

With a 200-person capacity, engineering talent at the new office will help drive global product innovation in the Subscription Economy…

3 years ago

Khan World School at ASU Prep Accelerates Expansion Thanks to Exceptional Academic Performance by Pilot Cohort

Online Honors Program Enrolling Students in Grades 6-12 for 2023-24 School Year TEMPE, Ariz.--(BUSINESS WIRE)--Building on its successful pilot of…

3 years ago

Khan World School at ASU Prep Accelerates Expansion Thanks to Exceptional Academic Performance by Pilot Cohort

Online Honors Program Enrolling Students in Grades 6-12 for 2023-24 School Year TEMPE, Ariz.--(BUSINESS WIRE)--Building on its successful pilot of…

3 years ago

Khan World School at ASU Prep Accelerates Expansion Thanks to Exceptional Academic Performance by Pilot Cohort

Online Honors Program Enrolling Students in Grades 6-12 for 2023-24 School Year TEMPE, Ariz.--(BUSINESS WIRE)--Building on its successful pilot of…

3 years ago

InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases,…

3 years ago

� Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with…

3 years ago